Navigation Links
Abbott Scientists Create One Molecule With Two Antibody Functions
Date:10/18/2007

First Combination of Large Molecules to Show Drug-like Properties and

Manufacturing Feasibility

ABBOTT PARK, Ill., Oct. 18 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) reported today that its scientists are the first to discover a proprietary technology that combines the function and specificity of two or more monoclonal antibodies (mAbs) into one molecular entity that demonstrates drug-like properties and manufacturing feasibility. These molecules, called dual-variable domain Ig (DVD-Ig(TM)) (http://www.abbott.com/global/url/content/en_US/60.15:15/feature/Feature_0029.htm) , will allow for development of individual drug candidates that target multiple disease-causing molecules in various therapeutic categories.

Published online earlier this week in Nature Biotechnology (http://www.nature.com/nbt/journal/vaop/ncurrent/full/nbt1345.html), this landmark study demonstrates a completely new platform that may be relevant to cancer, autoimmune diseases and other complicated conditions in which multiple disease-mediators are at play. Simultaneous blockage of multiple targets using DVD-Ig agents may increase efficacy in comparison to inhibition of a single target using a mAb.

"Combining the specificity of two or more antibodies into one drug has been a significant challenge for researchers looking at next generation biologic therapies," said Abbott Scientists Chengbin Wu, Ph.D. and Tariq Ghayur, Ph.D., who designed the DVD-Ig molecules and led the research team. "Abbott's approach is remarkably versatile and efficient in creating a single molecular entity with drug-like properties and the ability to target multiple disease mediators. We are very excited about the doors this opens in drug development across a range of therapeutic areas."

The process of combining two or more mAbs involves the use of molecular biology techniques, such as polymerase chain reaction (PCR), to link the regions (variable domains) of two different antibodies that target specific disease-causing molecules. The resulting molecule has two different (dual) variable domains, each of which targets a different disease-causing antigen.

While other public and private research programs have endeavored to combine two antibodies into one entity, the results have been limited by poor pharmacokinetics, stability and manufacturing feasibility.

Addressing only one disease target with a traditional mAb can result in limited efficacy because the disease can progress on multiple levels. For example, in rheumatoid arthritis (RA) distinct disease mediators (mechanisms) contribute towards various aspects of the disease such as inflammation, angiogenesis, pannus formation (thickened layers of granulation tissue) and bone and cartilage erosion. Therefore, targeting two or more disease mechanisms in RA may show far greater efficacy than targeting a single mechanism.

Using the DVD-Ig technology, research teams at Abbott have already created a single drug candidate that targets multiple disease components, one of which is TNF-alpha, a well-established target in RA. Preclinical evaluation of this drug candidate is underway.

Abbott's DVD-Ig approach has distinct technological, scientific and drug development advantages compared to mAbs and to previous efforts to create a multi-specific antibody. The approach is compatible with any antibody, including humanized mAbs, fully-human mAbs and chimeric mAbs, and can potentially be extended beyond antibodies to receptor proteins and other, similar molecules. DVD-Ig drugs also may have improved efficacy because they target multiple disease-causing molecules, and can address redundant disease processes, in which two different molecules have the same disease-causing effect.

Abbott has completed technology validation on the DVD-Ig program, and is currently confirming process development and manufacturing for the technology platform. Concurrently, preclinical work has been conducted on a variety of combinations at Abbott to date.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.


'/>"/>
SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Abbott vs. Thailand has implications for innovation and access
2. A prognosis for GE and Abbott Diagnostics
3. Wisconsin court halts Abbotts sale of genotyping products
4. Wisconsin court affirms damages in Innogenetics, Abbott patent case
5. Abbott Labs campus in Kenosha could send ripples through local biotech
6. Abbott Executive Jim Tyree Takes IBIO Helm
7. Promega Announces Agreement with Abbott
8. UW computer scientists fighting computer virus "Cold War"
9. Scientists find way to make human collagen in lab
10. Wisconsin scientists to be recognized for innovative biofuel technology
11. UW-Madison scientists to mimic nature for newest cancer drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... ... Mitotech S.A, a Luxembourg based clinical stage biotechnology company, announced positive results of ... devastating genetic disease that leads to a sudden and rapid loss of central vision. ... 11778, 14484 and 3460 mutations and having experienced the onset of symptoms more than ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... rebrand and a name change to Fluence Analytics. , Fluence Analytics ... of polymer and biopharmaceutical manufacturing processes and R&D applications. The company’s patented ...
(Date:4/26/2017)... ... April 26, 2017 , ... Looking ... team-building and cooking events company, offers one-of-a-kind gifts, ranging from gourmet cooking experiences ... California cuisine, and guests leave inspired with new cooking tips and techniques, thanks ...
(Date:4/26/2017)... ... April 26, 2017 , ... NextSteps 2017, NetDimensions’ annual global ... this May on the following dates: , ?    London, UK from May 10-11, ... Learning and Performance Institute will be the opening keynote speaker at the ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, ... Hack the Genome hackathon at Microsoft,s headquarters ... two-day competition will focus on developing health and wellness ... Hack the Genome is the first ... tremendous. The world,s largest companies in the genomics, tech ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
Breaking Biology News(10 mins):